FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Non-steroidal anti-inflammatory drugs in equine orthopaedics...
Equine veterinary journal2022; 54(4); 636-648; doi: 10.1111/evj.13561

Non-steroidal anti-inflammatory drugs in equine orthopaedics.

Abstract: Orthopaedic disorders are commonly encountered in equine veterinary medicine, and non-steroidal anti-inflammatory drugs (NSAIDs) play an important role in the management of many equine orthopaedic disorders. There are multiple NSAIDs available for use in horses, including both non-selective and selective NSAIDS, and the body of literature evaluating the efficacy of these medications, their effects on normal and inflamed musculoskeletal tissues, and their side effects is broad. This review aims to summarise the current literature on the use of NSAIDs for equine orthopaedic disorders and examines new and future avenues for the management of inflammation in equine orthopaedics.
© 2022 The Authors. Equine Veterinary Journal published by John Wiley & Sons Ltd on behalf of EVJ Ltd.
Get Full Text
Publication Date: 2022-02-10 PubMed ID: 35076950PubMed Central: PMC9304133DOI: 10.1111/evj.13561Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study revolves around the use of non-steroidal anti-inflammatory drugs (NSAIDs) in managing orthopaedic disorders in horses. The paper provides a comprehensive review of different NSAIDs available, their effectiveness, their impacts on musculoskeletal tissues, as well as associated side effects.

Introduction to NSAIDs in Equine Orthopaedics

  • The research discusses the prevalent usage of non-steroidal anti-inflammatory drugs (NSAIDs) in equine veterinary medicine, specifically in dealing with orthopaedic disorders. These disorders commonly plague equine beings, thus making the role of NSAIDs crucial.
  • Notably, the study indicates that there are several NSAIDs available for treating horses. Some are selective, targeting specific sites of inflammation or pain, while others are non-selective, working in a broader sense.

Review of the Literature

  • The paper carries out an extensive literature review to analyze the efficacy of these drugs in managing orthopaedic conditions in horses.
  • It takes a holistic perspective, studying not only the effects of these medications on inflamed musculoskeletal tissues, but also their roles in normal tissues. Understanding how these drugs interact with normal and inflamed tissues is pivotal to assessing their overall effectiveness and potential side effects.
  • In addition to discussing the efficiency of these drugs, the study also delves into potential side effects, thus providing a comprehensive picture of NSAIDs’ impacts.

Future Directions

  • The concluding sections of the study give an overview of prospective directions for managing inflammation in equine orthopaedics.
  • It addresses potential advancements in NSAID formulations or novel therapies that might emerge in the future to better manage equine orthopaedic disorders.
  • While focusing on existing drugs, the study doesn’t lose sight of future improvements, hence ushering readers into what might be the future of equine orthopaedic management.

Implication of the Study

  • The research underscores the critical role that NSAIDs play in managing equine orthopaedic disorders and the need for further research to maximize their efficiency and minimize drawbacks.
  • Information from this review can guide veterinary practitioners in effectively selecting and administering NSAIDs for managing equine orthopaedic issues.
  • Furthermore, insights gained from this study could stimulate more research into drug optimization and development of new drugs, thereby improving therapeutic outcomes for equine beings.

Cite This Article

APA
Jacobs CC, Schnabel LV, McIlwraith CW, Blikslager AT. (2022). Non-steroidal anti-inflammatory drugs in equine orthopaedics. Equine Vet J, 54(4), 636-648. https://doi.org/10.1111/evj.13561

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 54
Issue: 4
Pages: 636-648

Researcher Affiliations

Jacobs, Carrie C
  • Department of Clinical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
Schnabel, Lauren V
  • Department of Clinical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
McIlwraith, C Wayne
  • C. Wayne McIlwraith Translational Medicine Institute (TMI), Colorado State University, Fort Collins, Colorado, USA.
Blikslager, Anthony T
  • Department of Clinical Sciences, North Carolina State University, Raleigh, North Carolina, USA.

Conflict of Interest Statement

No competing interests have been declared.

References

This article includes 105 references
  1. Kaneene JB, Ross WA, Miller R. The Michigan equine monitoring system. II. Frequencies and impact of selected health problems.. Prev Vet Med 1997;29:277–92.
    pubmed: 9234436
  2. United States Department of Agriculture. Baseline reference of equine health and management in the United States: 2015. Report 1.. Washington DC: United States Department of Agriculture; 2015.
  3. Egenvall A, Tranquille CA, Lönnell AC, Bitschnau C, Oomen A, Hernlund E. Days‐lost to training and competition in relation to workload in 263 elite show‐jumping horses in four European countries.. Prev Vet Med 2013;112:387–400.
    pubmed: 24125697
  4. Dyson PK, Jackson BF, Pfeiffer DU, Price JS. Days lost from training by two‐ and three‐year‐old Thoroughbred horses: a survey of seven UK training yards.. Equine Vet J 2008;40(7):650–7.
    pubmed: 19165934
  5. Wilsher S, Allen WR, Wood JLN. Factors associated with failure of Thoroughbred horses to train and race.. Equine Vet J 2006;38(2):113–8.
    pubmed: 16536379
  6. Al B, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain.. Cell J 2009;139(2):267–84.
    pmc: PMC2852643pubmed: 19837031
  7. Costigan M, Woolf CJ. Pain: molecular mechanisms.. J Pain 2000;1(3 suppl):35–44.
    pubmed: 14622841
  8. Cook VL, Blikslager AT. The use of nonselective anti‐inflammatory drugs in critically ill horses.. J Vet Emerg Crit Care 2015;25(1):76–88.
    pubmed: 25521286
  9. Plumb DC. Plumb’s veterinary drug handbook.. 9th edn. Hoboken, New Jersey: John Wiley & Sons, Inc; 2018.
  10. Duz M, Marshall JF, Parkin TD. Proportion of nonsteroidal anti‐inflammatory drug prescription in equine practice.. Equine Vet J 2019;51:147–53.
    pubmed: 30048005
  11. Taylor JB, Walland A, Lees P, Gerring EL, Maitho TE, Millar JD. Biochemical and haematological effects of a revised dosage schedule of phenylbutazone in horses.. Vet Rec 1983;112(26):599–602.
    pubmed: 6879987
  12. Collins LG, Tyler DE. Phenylbutazone toxicosis in the horse: a clinical study.. J Am Vet Med Assoc 1984;184:699–703.
    pubmed: 6725103
  13. Snow DH, Douglas TA, Thompson H, Parkins JJ, Holmes PH. Phenylbutazone toxicosis in Equidae: a biochemical and pathologic study.. Am J Vet Res 1981;42(10):1754–9.
    pubmed: 7325437
  14. MacKay RJ, French TW, Nguyen HT, Mayhew IG. Effects of large doses of phenylbutazone administration to horses.. Am J Vet Res 1983;44(5):774–80.
    pubmed: 6869982
  15. Hu HH, MacAllister CG, Payton ME, Erkert RS. Evaluation of the analgesic effects of phenylbutazone administered at a high or low dosage in horses with chronic lameness.. J Am Vet Med Assoc 2005;226(3):414–7.
    pubmed: 15702692
  16. Foreman JH, Barange A, Lawrence LM, Hungerford LL. Effects of a single‐dose intravenous phenylbutazone on experimentally induced, reversible lameness in the horse.. J Vet Pharmacol Ther 2008;31(1):39–44.
    pubmed: 18177317
  17. Raekallio M, Taylor PM, Bennett RC. Preliminary investigations of pain and analgesia assessment in horses administered phenylbutazone or placebo after arthroscopic surgery.. Vet Surg 1997;26:150–5.
    pubmed: 9068166
  18. Frisbie DD, McIlwraith CW, Kawcak CE, Werpy NM, Pearce GL. Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis.. Am J Vet Res 2009;70(2):210–5.
    pubmed: 19231953
  19. Peek SF, Semrad SD, Perkins GA. Clostridial myonecrosis in horses (37 cases 1985–2000).. Equine Vet J 2003;35(1):86–92.
    pubmed: 12553469
  20. Anderson FL, Secombe CJ, Lester GD. Clostridial myonecrosis, haemolytic anemia, hepatopathy, osteitis, and transient hypertrophic cardiomyopathy after intramuscular injection in a Thoroughbred gelding.. Aust Vet J 2013;91(5):204–8.
    pubmed: 23614516
  21. Knych HK, Arthur RM, Gretler SR, McKemie DS, Goldin S, Kass PH. Pharmacokinetics of transdermal flunixin meglumine and effects on biomarkers of inflammation in horses.. J Vet Pharmacol Ther 2021;44:745–53.
    pubmed: 34173263
  22. Foreman JH, Bergstrom BE, Golden KS, Roark JJ, Coren DS, Foreman CR. Dose titration of the clinical efficacy of intravenously administered flunixin meglumine in a reversible model of equine foot lameness.. Equine Vet J 2012;44(suppl. 43):17–20.
    pubmed: 23447872
  23. Foreman JH, Grubb TL, Inoue OJ, Banner SE, Ball KT. Efficacy of single‐dose intravenous phenulbutazone and flunixin meglumine before, during, and after exercise in an experimental reversible model of foot lameness in horses.. Equine Vet J 2010;42(suppl 38):601–5.
    pubmed: 21059067
  24. Foreman JH, Ruemmler R. Phenylbutazone and flunixin meglumine used singly or in combination in experimental lameness in horses.. Equine Vet J 2011;43(suppl 40):12–7.
    pubmed: 22082440
  25. Erkert RS, MacAllister CG, Payton ME, Clarke CR. Use of force plate analysis to compare the analgesic effects of intravenous administration of phenylbutazone and flunixin meglumine in horses with navicular syndrome.. Am J Vet Res 2005;66(2):284–8.
    pubmed: 15757129
  26. Keegan KG, Messer NT, Reed SK, Wilson DA, Kramer J. Effectiveness of administration of phenylbutazone alone or concurrent administration of phenylbutazone and flunixin meglumine to alleviate lameness in horses.. Am J Vet Res 2008;69(2):167–73.
    pubmed: 18241011
  27. Knych HK, Arthur RM, McKemie DS, Baden RW, Seminoff K, Kass PH. Pharmacokinetics and anti‐inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised Thoroughbred horses.. Equine Vet J 2021;53:102–16.
    pubmed: 32145701
  28. . 2020 USEF guidelines and rules for drugs and medications.. Columbus, Ohio: United States Equestrian Federation; 2020.
  29. Johnson CB, Taylor PM, Young SS, Brearley JC. Postoperative analgesia using phenylbutazone, flunixin, or carprofen in horses.. Vet Rec 1993;133(14):336–8.
    pubmed: 8236675
  30. Letendre LT, Tessman RK, McClure SR, Kvaternick VJ, Fischer JB, Hanson PD. Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses.. Am J Vet Res 2008;69(11):1399–405.
    pubmed: 18980421
  31. Cox S, Villarino N, Sommardahl C, Kvaternick V, Zarabadipour C, Siger L. Disposition of firocoxib in equine plasma after an oral loading dose and a multiple dose regimen.. Vet J 2013;198:382–5.
    pubmed: 24076125
  32. Orsini JA, Ryan WG, Carithers DS, Boston RC. Evaluation of oral administration of firocoxib for the management of musculoskeletal pain and lameness associated with osteoarthritis in horses.. Am J Vet Res 2012;73(5):664–71.
    pubmed: 22533398
  33. Back W, MacAllister CG, van Heel MCV, Pollmeier M, Hanson PD. The use of force plate measurements to titrate the dosage of a new COX‐2 inhibitor in lame horses.. Equine Vet J 2009;41(3):309–12.
    pubmed: 19469242
  34. Doucet MY, Bertone AL, Hendrickson D, Hughes F, MacAllister C, McClure S. Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis.. J Am Vet Med Assoc 2008;232(1):91–7.
    pubmed: 18167116
  35. Beretta C, Garavaglia G, Cavalli M. COX‐1 and COX‐2 inhibition in horse blood by phenylbutazone, flunixin, carprofen, and meloxicam: an in vitro analysis.. Pharmacol Res 2005;52:302–6.
    pubmed: 15939622
  36. Class UCVM of 2016, Banse H, Cribb AE. Comparative efficacy of oral meloxicam and phenylbutazone in 2 experimental pain models in the horse.. Can Vet J 2017;58:157–67.
    pmc: PMC5234315pubmed: 28216685
  37. Toutain P, Cester CC. Pharmacokinetic‐pharmacodynamic relationships and dose response to meloxicam in horses with induced arthritis in the right carpal joint.. Am J Vet Res 2004;65(11):1533–41.
    pubmed: 15566092
  38. de Grauw JC, van de Lest CHA, Brama PAJ, Rambags BPB, van Weeren PR. In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis.. Equine Vet J 2009;41(7):693–9.
    pubmed: 19927589
  39. Persson‐Sjodin E, Hernlund E, Pfau T, Andersen PH, Forsstrom KH, Rhodin M. Effect of meloxicam treatment on movement asymmetry in riding horses in training.. PLoS One 2019;14(8):e0221117.
    doi: 10.1371/journal.pone.0221117pmc: PMC6692031pubmed: 31408491google scholar: lookup
  40. Bryant CE, Farnfield BA, Janicke HJ. Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa B.. Am J Vet Res 2003;64(2):211–5.
    pubmed: 12602591
  41. McKellar QA, Bogan JA, von Fellenberg RL, Ludwig B, Cawley GD. Equine. Vet J. 1991;23(4):280–4.
    pubmed: 1915228
  42. McIlwraith CW, Frisbie DD. Nonsteroidal anti‐inflammatory drugs.. In: McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR, editors. Joint disease in the horse, 2nd edn. St. Louis, MO: Elsevier; 2016. p. 192–201.
  43. Landoni MR, Lees P. Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses.. J Vet Pharmacol Ther 1995;18:438–41.
    pubmed: 8789698
  44. Brink P, DeGraves F, Ravis WR, Johansen D, Campbell JD, Duran SH. Stereospecific pharmacokinetics of free and protein bound ketoprofen in serum and synovial fluid of horses after intravenous and intramuscular administration.. Am J Vet Res 1998;59(6):739–43.
    pubmed: 9622744
  45. Owens JG, Kamerling SG, Stanton SR, Keowen ML. Effects of ketoprofen and phenylbutazone on chronic hoof pain and lameness in the horse.. Equine Vet J 1995;27(4):296–300.
    pubmed: 8536666
  46. Owens JG, Kamerling SG, Standon SR, Keowen ML, Prescott‐Mathews JS. Effects of pretreatment with ketoprofen and phenylbutazone on experimentally induced synovitis in horses.. Am J Vet Res 1996;57(6):866–74.
    pubmed: 8725815
  47. Davis JL, Papich MG, Morton AJ, Gayle J, Blikslager AT, Campbell NB. Pharmacokinetics of etodolac in the horse following oral and intravenous administration.. J Vet Pharmacol Ther 2007;30:43–8.
    pubmed: 17217400
  48. Morton AJ, Campbell NB, Gayle JM, Redding WR, Blikslager AT. Preferential and non‐selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide‐induced synovitis.. Res Vet Sci 2005;78:189–92.
    pubmed: 15563928
  49. Symonds KD, MacAllister CG, Erkert RS, Payton ME. Use of force plate analysis to assess the analgesic effects of etodolac in horses with navicular syndrome.. Am J Vet Res 2006;67(4):557–61.
    pubmed: 16579745
  50. Bianco AW, Constable PD, Cooper BR, Taylor SD. Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single‐dose administration.. J Vet Pharmacol Ther 2015;39:167–75.
    pubmed: 26416348
  51. Bianco AW, Moore GE, Cooper BR, Taylor SD. In vitro anti‐LPS dose determination of ketorolac tromethamine and in vivo safety of repeating dosing in healthy horses.. J Vet Pharmacol Therap 2018;41:98–104.
    pubmed: 28600856
  52. Grady SE, Lescun TB, Moore GE, Cooper BR, Davern AJ, Brunner TJ. Ketorolac is not more effective than flunixin meglumine or phenylbutazone in reducing foot pain in horses.. J Equine Vet Sci 2020;94:103204.
    doi: 10.1016/j.jevs.2020.103204pubmed: 33077087google scholar: lookup
  53. Lynn RC, Hepler DI, Kelch WJ, Bertone JJ, Smith BL, Vatistas NJ. Double‐blinded placebo‐controlled clinical field trial to evaluate the safety and efficacy of topically applied 1% diclofenac liposomal cream for the relief of lameness in horses.. Vet Ther 2004;5(2):128–38.
    pubmed: 15468010
  54. Schlening JA, McClure SR, Evans RB, Hyde WG, Wulf LW, Kind AJ. Liposome‐based diclofenac for the treatment of inflammation in an acute synovitis model in horses.. J Vet Pharmacol Ther 2008;31:554–61.
    pubmed: 19000279
  55. Frean SP, Abraham LA, Lees A. In vitro stimulation of equine articular cartilage proteoglycan synthesis by hyaluronan and carprofen.. Res Vet Sci 1997;67:181–8.
    pubmed: 10502490
  56. Williams A, Smith JR, Allaway D, Harris P, Liddell S, Mobasheri A. Carprofen inhibits the release of matrix metalloproteinases 1, 3, and 13 in the secretome of an explant model of articular cartilage stimulated with interleurkin 1B.. Arthritis Res Ther 2013;15(6):R223.
    pmc: PMC3978949pubmed: 24373218doi: 10.1186/ar4424google scholar: lookup
  57. Armstrong S, Lees P. Effects of carprofen (R and S enantiomers and racemate) on the production of IL‐1, IL‐6, and TNF‐a by equine chondrocytes and synoviocytes.. J Vet Pharmacol Ther 2002;25:145–53.
    pubmed: 12000535
  58. de Grauw JC, van Loon JPAM, van de Lest CHA, Brunott A, van Weeren PR. In vivo effects of phenylbutazone on inflammation and cartilage‐derived biomarkers in equine joints with acute synovitis.. Vet J 2014;201:51–6.
    pubmed: 24888681
  59. Clegg PD, Jones MD, Carter SD. The effect of drugs commonly used in the treatment of equine articular disorders on the activity of equine matrix metalloproteinase‐2 and 9.. J Vet Pharmacol Ther 1998;21:406–13.
    pubmed: 9811443
  60. Beluche LA, Bertone AL, Anderson DE, Rohde C. Effects of oral administration of phenylbutazone to horses on in vitro articular cartilage metabolism.. Am J Vet Res 2001;62:1916–21.
    pubmed: 11763181
  61. Fradette ME, Celeste C, Richard H, Beauchamp G, Laverty S. Effects of continuous oral administration of phenylbutazone on biomarkers of cartilage and bone metabolism.. Am J Vet Res 2007;68:128–33.
    pubmed: 17269876
  62. Jolly WT, Whittem T, Jolly AC, Firth BC. The dose related effects of phenylbutazone and a methylprednisolone acetate formulation (Depo‐Medrol) on cultured explants of equine carpal articular cartilage.. J Vet Pharmacol Ther 1995;18:429–37.
    pubmed: 8789695
  63. Moses VS, Hardy J, Bertone AL, Weisbrode SE. Effects of anti‐inflammatory drugs on lipopolysaccharide‐challenged and ‐unchallenged equine synovial explants.. Am J Vet Res 2001;62:54–60.
    pubmed: 11197561
  64. Rohde C, Anderson DE, Bertone AL, Weisebrode SE. Effects of phenylbutazone on bone activity and formation in horses.. Am J Vet Res 2000;61:537–43.
    pubmed: 10803649
  65. Behfar M, Hobbenaghi R, Sarrafzadeh‐Rezaei F. Effects of flunixin meglumine on experimental tendon wound healing: a histopathological and mechanical study in rabbits.. Vet Res Forum 2013;4(4):233–8.
    pmc: PMC4279621pubmed: 25568677
  66. Pelletier JP, Raynauld JP, Dorais M, Bessette L, Dokoupilova E, Morin F. An international, multicentre, double‐blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis.. Rheumatology 2020;59:3858–68.
    pmc: PMC7733720pubmed: 32521015
  67. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption.. J Pharmacol Exp Ther 2001;297(2):638–45.
    pubmed: 11303053
  68. Mastenbergen SC, Marijnissen AC, Vianen ME, Zoer B, van Roermund PM, Bijlsma JW. Inhibition of COX‐2 by celecoxib in the canine groove model of osteoarthritis.. Rheumatology 2006;45:405–13.
    pubmed: 16287921
  69. Tamura D, Saito T, Murata K, Kawashima M, Asano R. Celecoxib exerts antitumor effects in canine mammary tumor cells via COX‐2‐independent mechanisms.. Int J Oncol 2015;46(3):1393–404.
    pubmed: 25571853
  70. Subhahar MB, Singh J, Albert PH, Kadry AM. Pharmacokinetics, metabolism and excretion of celecoxib, a selective cyclooxygenase‐2 inhibitor, in horses.. J Vet Pharmacol Ther 2019;42:518–24.
    pubmed: 30888074
  71. King JN, Dawson J, Esser RE, Fujimoto R, Kimble EF, Maniara W. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase‐2.. J Vet Pharmacol Ther 2009;32:1–17.
    pubmed: 19161451
  72. Kamata M, King JN, Seewald W, Sakakibara N, Yamashita K, Nishimura R. Comparison of injectable robenacoxib versus meloxicam for perioperative use in cats: results of a randomized clinical trial.. Vet J 2012;193(1):114–8.
    pubmed: 22227226
  73. King JN, King S, Budsberg SC, Lascelles BDX, Bienhoff SE, Roycroft LM. Clinical safety of robenacoxib in feline osteoarthritis: results of a randomized, blinded, placebo‐controlled clinical trial.. J Feline Med Surg 2016;18(8):632–42.
    pmc: PMC10816385pubmed: 26058587
  74. Bennett D, Eckersall PD, Waterson M, Marchetti V, Rota A, McCulloch E. The effect of robenacoxib on the concentration of C‐reactive protein in synovial fluid from dogs with osteoarthritis.. BMC Vet Res 2013;9(1):42.
    pmc: PMC3610148pubmed: 23452411
  75. Marshall JF, Bhatnagar AS, Bowman SG, Howard CM, Morris NN, Skorich DA. Evaluation of the cyclooxygenase selectivity of robenacoxib and its effect on recovery of ischemia‐injured jejunal mucosa in horses.. Am J Vet Res 2011;72:226–32.
    pubmed: 21281197
  76. Richardson LM, Whitfield‐Cargile CM, Cohen ND, Chamoun‐Emanuelli AM, Dockery HJ. Effect of selective versus non‐selective cyclooxygenase inhibitors on gastric ulceration scores and intestinal inflammation in horses.. Vet Surg 2018;47:784–91.
    pubmed: 30094858
  77. Whitfield‐Cargile CM, Am C‐E, Cohen ND, Richardson LM, Ajami NJ, Dockery HJ. Differential effects of selective and non‐selective cyclooxygenase inhibitors on fecal microbiota in adult horses.. PLoS One 2018;13(8):e0202527.
    doi: 10.1371/journal.pone.0202527pmc: PMC6107168pubmed: 30138339google scholar: lookup
  78. Patrono C. Cardiovascular effects of cyclooxygenase‐2 inhibitors: a mechanistic and clinical perspective.. Br J Clin Pharmacol 2016;82:957–64.
    pmc: PMC5137820pubmed: 27317138
  79. Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology . LXXXIII: classification of prostanoid receptors, updating 15 years of progress.. .
    pubmed: 21752876
  80. Shaw KK, Rausch‐Derra LC, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation.. Vet Med Sci 2016;2:3–9.
    pmc: PMC5645826pubmed: 29067176
  81. Raush‐Derra LC, Rhodes L, Freshwater L, Hawks R. Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs.. J Vet Pharmacol Ther 2016;39:566–71.
    pubmed: 27027634
  82. Raush‐Derra LC, Huebner M, Rhodes L. Evaluation of the safety of long‐term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritis pain and inflammation, in healthy dogs.. Am J Vet Res 2015;76:853–9.
    pubmed: 26413822
  83. Cox S, Sommardahl FC, Davis R, Bergman J, Doherty T. Determination of grapiprant plasma and urine concentration in horses.. Vet Anaesth Analg 2020;47:705–9.
    pubmed: 32439238
  84. Knych HK, Seminoff K, McKemie DS. Detection and pharmacokinetics of grapiprant following oral administration to exercised Thoroughbred horses.. Drug Test Anal 2018;10:1237–43.
    pubmed: 29575649
  85. Chang DS, Hsu E, Hottinger DG, Cohen SP. Anti‐nerve growth factor in pain management: current evidence.. J Pain Res 2016;9:373–83.
    pmc: PMC4908933pubmed: 27354823
  86. Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J. Efficacy, safety, and tolerability of fulranumab, an anti‐nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain.. Pain 2013;154(10):1910–9.
    pubmed: 23748114
  87. Lascelles BDX, Knazovicky D, Case B, Freire M, Innes JF, Drew AC. A canine‐specific anti‐nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease‐ associated pain.. BMC Vet Res 2015;11:101.
    doi: 10.1186/s12917-015-0413-xpmc: PMC4419463pubmed: 25926287google scholar: lookup
  88. Gruen ME, Myers JAE, Lascelles BDX. Efficacy and safety of an anti‐nerve growth factor antibody (Frunevetmab) for the treatment of degenerative joint disease‐associated chronic pain in cats: a multisite pilot field study.. Front Vet Sci 2021;8:610028.
    doi: 10.3389/fvets.2021.610028pmc: PMC8195238pubmed: 34124212google scholar: lookup
  89. Frisbie DD, King M, Nelson B, Gearing D. In vivo assessment of anti‐nerve growth factor administration either systemically or locally using models of joint disease.. Osteoarthr Cartil 2017;25(S1):S442.
  90. Riggin CN, Tucker JJ, Soslowsky LJ, Kuntz AF. Intra‐articular tibiofemoral injection of a nonsteroidal anti‐inflammatory drug had no detrimental effects on joint mechanics in a rat model.. J Ortho Res 2014;32(11):1512–9.
    pmc: PMC4404033pubmed: 24981310
  91. Bellamy JL, Goff BJ, Sayeed SA. Economic impact of ketorolac vs corticosteroid intra‐articular knee injections for osteoarthritis: a randomized, double‐blind, prospective study.. J Arthroplasty 2016;31:S293–7.
    pubmed: 27402605
  92. Xu J, Qu Y, Li H, Zu A, Jiang T, Chong Z. Effect of intra‐articular ketorolac versus corticosteroid injection for knee osteoarthritis.. Orthop J Sports Med 2020;8(4).
    doi: 10.1177/2325967120911126pmc: PMC7153200pubmed: 32313809google scholar: lookup
  93. Bernthal NM, Hart CM, Sheth KR, Bergese SD, Ho HS, Apfel CC. Local and intra‐articular administration of non‐steroidal anti‐inflammatory drugs for pain management in orthopedic surgery.. Am J Ther 2020.
    doi: 10.1097/MTJ.0000000000001309pubmed: 33315593google scholar: lookup
  94. Larsen SW, Frost AB, Ostergaard J, Thomsen MH, Jacobsen S, Skonberg C. In vitro and in vivo characteristics of celecoxib in situ formed suspensions for intra‐articular administration.. J Pharm Sci 2011;100(10):4330–7.
    pubmed: 21598256
  95. Petit A, Redout EM, van de Lest CH, de Grauw JC, Müller B, Meyboom R. Sustained intra‐articular release of celecoxib from in situ forming gels made of acetyl‐capped PCLA‐PEG‐PCLA triblock copolymers in horses.. Biomaterials 2015;53:426–36.
    pubmed: 25890740
  96. Cokelaere SM, Plomp SGM, de Boef E, de Leeuw M, Bool S, van de Lest CHA. Sustained intra‐articular release of celecoxib in an equine related LPS synovitis model.. Eur J Pharm Biopharm 2018;128:327–36.
    pubmed: 29729412
  97. Andrews FM, Sifferman RL, Bernard W, Hughes FE, Holste JE, Daurio CP. Efficacy of omeprazole paste in the treatment and prevention of gastric ulcers in horses.. Equine Vet J 1999;31(suppl 29):81–6.
    pubmed: 10696301
  98. Ricord M, Andrews FM, Yniguez FJM, Keowen M, Garza F, Paul L. Impact of concurrent treatment with omeprazole on phenylbutazone‐induced equine gastric ulcer syndrome (EGUS).. Equine Vet J 2021;53(2):356–63.
    pubmed: 32697849
  99. Whitfield‐Cargile CM, Coleman MC, Cohen ND, Chamoun‐Emanuelli AM, DeSolis CN, Tetrault T. Effects of phenylbutazone alone or in combination with a nutritional therapeutic on gastric ulcers, intestinal permeability, and fecal microbiota in horses.. J Vet Intern Med 2021;35:1121–30.
    pmc: PMC7995434pubmed: 33656183
  100. Sharma CV, Mehta V. Paracetamol: mechanisms and updates.. Cont Edu Anaest Crit Care Pain 2014;14(4):153–8.
  101. West E, Bardell D, Morgan R, Senior M. Use of acetaminophen (paracetamol) as a short‐term adjunctive analgesic in a laminitic pony.. Vet Anaesth Analg 2011;38:521–2.
    pubmed: 21831061
  102. Foreman JH, Foreman CR, Bergstrom BE. Acetaminophen/paracetamol efficacy in a reversible model of equine foot pain.. Proceedings American Association Equine Practitioners 2016;62:295–6.
  103. Tavanaeimanesh H, Azarnoosh A, Ashar FS, Dehghan MM, Mohebbi Z, Akbarinejad V. Comparison of analgesic effects of a constant rate infusion of both tramadol and acetaminophen versus those of infusions of each individual drug in horses.. J Equine Vet Sci 2018;64:101–6.
    pubmed: 30973144
  104. Dakin SG, Dudhia J, Smith RKW. Resolving an inflammatory concept: the importance of inflammation and resolution in tendinopathy.. Vet Immunol Immunopathol 2014;158:121–7.
    pmc: PMC3991845pubmed: 24556326
  105. Serhan CN, Takano T, Chiang N, Gronert K, Clish CB. Formation of endogenous “anti‐inflammatory” lipid mediators by transcellular biosynthesis. Lipoxins and aspirin‐triggered lipoxins inhibit neutrophil recruitment and vascular permeability.. Am J Respir Crit Care Med 2000;161:S95–S101.
    pubmed: 10673235
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.